Cited 21 times in
Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.